The dream of a disease free world

Our approach with Efthalia aims to treat Type-1 Diabetes by harnessing the power of stem cells to create insulin producing beta cells

Type-1 Diabetes is a type of autoimmune disorder in which the immune system attacks insulin producing beta cells in the pancreas. This causes the pancreas to produce little to no insulin leading to elevated and erratic blood sugar levels that cause many other dangerous complications. Type-1 Diabetes is a chronic disease that requires frequent monitoring and insulin infusion, which significantly lowers the quality of life of the patient.

Current Line of Treatment



  • Life long monitering and medication required
  • Disruptive and cumbersome lifestyle
  • Difficult to keep blood sugar levels in check

Significant Worldwide Burden

Annual Cases


9 m

Efthalia is a next-generation allogenic ex vivo cell therapy in which a medical device that produces insulin inside the body is implanted into Type-1 Diabetics. This implant contains allogenic progenitor cells that continuously give birth to insulin producing beta cells. These allogenic insulin producing Beta cells will create a long lasting treatment for Type-1 Diabetics by endogenously producing the right amount of insulin as and when required by the body. Unlike external glucose monitors, the beta cells have the ability to continuously regulate blood sugar and secrete the desired amount of insulin, which keeps the blood sugar levels in check.

Check out some of the other next-generation living therapeutics that are being developed by Micro CRISPR.